UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.


Decrease the text size \| Restore text size \| Increase the text size

SLCO1B3

Synonyms: LST-3TM13, LST3, OATP1B3, OATP8, SLC21A8

Entrez Gene Link

Expression Data
Substrate Information
Inhibitor Information
Clinical Drug-drug Interactions

Expression Data

Expression data for other tissues could be found in http://pharmacogenetics.ucsf.edu/gtex/index.html

Asterisk indicates important transporters in the organ as identified in the organ diagram.

Organ	Source	Relative Expression
Kidney	Mean across all PMT Samples	`0.0689`
Liver*	Mean across all PMT Samples	`8.511`

Note that relative expression values should only be compared between entries of the same source.

Back to top

In Vitro Substrates

Substrate	Km (μM)	Cell System	Reference
17beta-Glucuronosyl estradiol	5.4	HEK293-OATP1B3	Cui, 2001
Amanitin	3.7	MDCK II-OATP1B3	Letschert, 2006
Amanitin	3.7	MDCK--OATP1B3	McFeely, 2019
Atorvastatin³	0.73	HEK293-OATP1B3	Karlgren, 2012
Bilirubin	0.0391	OATP1B3-expressing oocytes	Briz, 2003
Bosentan³	141	CHO-OATP1B3	Treiber, 2007
Bromsulphthalein	3.3	HEK293-OATP1B3	Cui, 2001
Bromsulphthalein	0.4	OATP1B3-expressing oocytes	Kullak-Ublick, 2001
Bromsulphthalein	2.2	MDCKII-ABCC2-OATP1B3	Kopplow, 2005
Cefadroxil	4.15	oocytes-OATP1B3	Nakakariya, 2008
Cefazolin	3.89	oocytes-OATP1B3	Nakakariya, 2008
Cefditoren	5.87	oocytes-OATP1B3	Nakakariya, 2008
Cefmetazole	0.71	oocytes-OATP1B3	Nakakariya, 2008
Cefoperazone	1.95	oocytes-OATP1B3	Nakakariya, 2008
Cephalexin	1.19	oocytes-OATP1B3	Nakakariya, 2008
Cholecystokinin octapeptide	3.82	HEK293-OATP1B3	Hirano, 2004
Cholecystokinin octapeptide	16.5	CHO-OATP1B3	Poirier, 2009
Cholyl-glycylamido-fluorescein (CGamF)	2.2	CHO-OATP1B3	Annaert, 2010
Digoxin	ND	OATP1B3-expressing oocytes	Kullak-Ublick, 2001
Dioscin	2.08	HEK293-OATP1B3	McFeely, 2019
Docetaxel³	2.2	CHO-OATP1B3	de, 2012
Estradiol-17beta-glucuronide^1,2	24.6	HEK293-OATP1B1	Hirano, 2004
Estradiol-17beta-glucuronide^1,2	15.8	CHO-OATP1B3	Gui, 2008
Estrone sulfate^1,2	58	CHO-OATP1B3	Gui, 2008
Fexofenadine³	108	HEK293-OATP1B3	Shimizu, 2005
Fluo-3	3.1	CHO-OATP1B3	Gui, 2008
Fluvastatin	7	MDCK II-OATP1B3	Kopplow, 2005
Gadoxetic Acid	0.532	HEK293-OATP1B3	Nassif, 2012
Glibenclamide	15.36	HEK-OATP1B3	Chen, 2018
Glipizide	41.29	HEK293-OATP1B3	Chen, 2018
Glycoursodeoxycholate	24.7	HEK293-OATP1B3	Maeda, 2006
Irbesartan	11.9	HEK293-OATP1B3	McFeely, 2019
Mesalazine	77.4	HEK293-OATP1B3	Konig, 2011
Methotrexate	24.7	OATP1B3-expressing oocytes	Abe, 2001
Methotrexate	39.4	MDCK-OATP1B3	Abe, 2001
Monoglucuronosyl bilirubin	0.5	HEK293-OATP1B3	Cui, 2001
Nafcillin	0.07	oocytes-OATP1B3	Nakakariya, 2008
Nilotinib	7.84	HEK293-OATP1B3	McFeely, 2019
Olmesartan	71.8	OATP1B3-expressing oocytes	Nakagomi-Hagihara, 2006
Olmesartan	44.2	HEK293-OATP1B3	Yamada, 2007
Paclitaxel³	6.79	OATP1B3-expressing oocytes	Smith, 2005
Pitavastatin^1,3	3.25	HEK293-OATP1B3	Hirano, 2004
Pitavastatin^1,3	3.8	OATP1B3-expressing oocytes	Fujino, 2005
Rifampicin²	2.3	OATP1B3-expressing oocytes	Vavricka, 2002
Rosuvastatin^1,3	9.8	HeLa-OATP1B3	Ho, 2006
Rosuvastatin^1,3	14.2	HEK293-OATP1B3	Kitamura, 2008
Taurocholate	5.8	OATP1B3-expressing oocytes	Abe, 2001
Tauroursodeoxycholate	15.9	HEK293-OATP1B3	Maeda, 2006
Telmisartan¹	0.81	HEK293-OATP1B3	Ishiguro, 2006
Telmisartan glucuronide	3.4	HEK293-OATP1B3	Ishiguro, 2008
Triiodothyronine	6.4	OATP1B3-expressing oocytes	Abe, 2001
Valsartan	18.2	HEK293-OATP1B3	Kreel, 1991
Valsartan	18.2	HEK293-OATP1B3	Yamashiro, 2006
Valsartan	23.5	CHO-OATP1B3	Poirier, 2009
Vandetanib	4.37	CHO-OATP1B3	McFeely, 2019

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022

In Vitro Inhibitors

Inhibitor	IC50 (μM)	Ki (μM)	Substrate used	Cell System	Reference
17beta-estradiol	12.9		Estradiol-17beta-glucuronide^1,2	CHO-OATP1B3	Gui, 2008
Amprenavir	19.1	13.1	Cholyl-glycylamido-fluorescein (CGamF)	CHO-OATP1B3	Annaert, 2010
Amprenavir	38		Estradiol-17beta-glucuronide^1,2	HEK-OATP1B3	Chiou, 2014
Antamanide	0.7	0.7	Amanitin	MDCK II-OATP1B3	Letschert, 2006
Antamanide	15		Bromsulphthalein	MDCK II-OATP1B3	Letschert, 2006
Asunaprevir³	0.65		CCK-8¹	HEK293-OATP1B3	Furihata, 2014
Atazanavir	3	2	Cholyl-glycylamido-fluorescein (CGamF)	CHO-OATP1B3	Annaert, 2010
Atazanavir	0.4	0.37	Estradiol-17beta-glucuronide^1,2	HEK293-OATP1B3	Karlgren, 2012
Boceprevir	4.9		Bromsulphthalein	MDCKII-OATP1B3	Chu, 2013
Bromsulphthalein	3		Amanitin	MDCK II-OATP1B3	Letschert, 2006
Bromsulphthalein	1.4	1	Cholyl-glycylamido-fluorescein (CGamF)	CHO-OATP1B3	Annaert, 2010
Carbamazepine	510		Estradiol-17beta-glucuronide^1,2	CHO-OATP1B3	Gui, 2008
Carfilzomib	0.9		FMTX	CHO-OATP1B3	Leibovici, 1989
Cholecystokinin octapeptide	10		Amanitin	MDCK II-OATP1B3	Letschert, 2006
Clarithromycin⁴	32		Bromsulphthalein	HEK293-OATP1B3	Seithel, 2007
Cyclosporine^2,4	0.3		Amanitin	MDCK II-OATP1B3	Letschert, 2006
Cyclosporine^2,4	0.8		Bosentan³	CHO-OATP1B1	Treiber, 2007
Cyclosporine^2,4	0.3		Bromsulphthalein	MDCK II-OATP1B3	Letschert, 2006
Cyclosporine^2,4	1.3	1.2	Estradiol-17beta-glucuronide^1,2	HEK293-OATP1B3	Karlgren, 2012
Cyclosporine^2,4	0.06		Rosuvastatin^1,3	HeLa-OATP1B3	Ho, 2006
Dabrafenib	4.7		Estradiol-17beta-glucuronide^1,2	HEK-MSRII-OATP1B3	Ellens, 2017
Daclatasvir	3.27		CCK-8¹	HEK293-OATP1B3	Furihata, 2014
Darolutamide	39.3		Atorvastatin³	HEK293-OATP1B3	Zurth, 2019
Darunavir	4.8	3.3	Cholyl-glycylamido-fluorescein (CGamF)	CHO-OATP1B3	Annaert, 2010
Dasatinib	5.76		Estradiol-17beta-glucuronide^1,2	HEK293-OATP1B3	Pahwa, 2017
Digoxin	1	0.7	Cholyl-glycylamido-fluorescein (CGamF)	CHO-OATP1B3	Annaert, 2010
Dovtinib	105.2		8-fluorescein-cAMP	HEK293-OATP1B3	Weiss, 2014
Doxorubicin	41	38	Estradiol-17beta-glucuronide^1,2	HEK293-OATP1B3	Karlgren, 2012
Dronedarone hydrochloride	1.12		FMTX	CHO-OATP1B3	Leibovici, 1989
Erlotinib	44	41	Estradiol-17beta-glucuronide^1,2	HEK293-OATP1B3	Karlgren, 2012
Erythromycin⁴	34		Bromsulphthalein	HEK293-OATP1B3	Seithel, 2007
Estrone sulfate^1,2	97.1		Cholecystokinin octapeptide	HEK293-OATP1B3	Ishiguro, 2006
Everolimus	3.7		Mycophenolic acid 7-O-glucuronide	HEK293-OATP1B3	Farasyn, 2019
Fexofenadine³	83.3		CCK-8¹	HEK293-OATP1B3	Shimizu, 2005
Fexofenadine³		205	Estrone sulfate^1,2	HEK293-OATP1B3	Shimizu, 2005
Fosinopril	5.19		FMTX	CHO-OATP1B3	Leibovici, 1989
Glibenclamide	9.8	8.1	Bromsulphthalein	HEK293-OATP1B3	Klatt, 2013
Glimepiride	40.9		Bromsulphthalein	HEK293-OATP1B3	Klatt, 2013
Gliquidone	1.17		FMTX	CHO-OATP1B3	Leibovici, 1989
Indinavir	12.3	8.5	Cholyl-glycylamido-fluorescein (CGamF)	CHO-OATP1B3	Annaert, 2010
Indinavir	16		Estradiol-17beta-glucuronide^1,2	HEK-OATP1B3	Chiou, 2014
Indometacin	41	8	Estradiol-17beta-glucuronide^1,2	HEK293-OATP1B3	Karlgren, 2012
Lapayonib	33.78		FMTX	CHO-OATP1B3	Leibovici, 1989
Lithocholate	6.8		Estradiol-17beta-glucuronide^1,2	CHO-OATP1B3	Gui, 2008
Lopinavir	2	1.4	Cholyl-glycylamido-fluorescein (CGamF)	CHO-OATP1B3	Annaert, 2010
Mevinolin	92.6		Estradiol-17beta-glucuronide^1,2	CHO-OATP1B3	Gui, 2008
Mifepristone	5.3		Estradiol-17beta-glucuronide^1,2	CHO-OATP1B3	Gui, 2008
MK-571	0.5	0.2	Amanitin	MDCK II-OATP1B3	Letschert, 2006
MK-571	0.3		Bromsulphthalein	MDCK II-OATP1B3	Letschert, 2006
Montelukast	15		Amanitin	MDCK II-OATP1B3	Letschert, 2006
Montelukast	0.5		Bromsulphthalein	MDCK II-OATP1B3	Letschert, 2006
Nateglinide³	45.6		CCK-8¹	MDCKII-OATP1B3	Meyer, 2014
Nobiletin	6.6		8-fluorescein-cAMP	HEK293 cells	Bajraktari-Sylejmani, 2020
Paclitaxel³	2		Amanitin	MDCK II-OATP1B3	Letschert, 2006
Paclitaxel³	4		Bromsulphthalein	MDCK II-OATP1B3	Letschert, 2006
Paclitaxel³	0.5		Estradiol-17beta-glucuronide^1,2	CHO-OATP1B3	Gui, 2008
Penicillin G	25		Amanitin	MDCK II-OATP1B3	Letschert, 2006
Pravastatin^1,3	62	57	Estradiol-17beta-glucuronide^1,2	HEK293-OATP1B3	Karlgren, 2012
Prednisolone phosphate	75		Amanitin	MDCK II-OATP1B3	Letschert, 2006
Probenecid		130	Fexofenadine³	HEK293-OATP1B3	Tahara, 2006
Rapamycin	0.4		FMTX	CHO-OATP1B3	Leibovici, 1989
Repaglinide³	5.6		Bromsulphthalein	HEK293-OATP1B3	Bachmakov, 2008
Rifampicin²	2.1		8-fluorescein-cAMP	HEK293 cells	Bajraktari-Sylejmani, 2020
Rifampicin²	0.8		Amanitin	MDCK II-OATP1B3	Letschert, 2006
Rifampicin²	1.6		Bosentan³	CHO-OATP1B1	Treiber, 2007
Rifampicin²		5	Bromsulphthalein	OATP1B3-expressing oocytes	Vavricka, 2002
Rifampicin²	1.5		Bromsulphthalein	MDCK II-OATP1B3	Letschert, 2006
Rifampicin²	1.3	0.9	Cholyl-glycylamido-fluorescein (CGamF)	CHO-OATP1B3	Annaert, 2010
Rifampicin²	2.6		Estradiol-17beta-glucuronide^1,2	CHO-OATP1B3	Gui, 2008
Rifampicin²	1.5	1.4	Estradiol-17beta-glucuronide^1,2	HEK293-OATP1B3	Karlgren, 2012
Rifamycin SV²		3	Bromsulphthalein	OATP1B3-expressing oocytes	Vavricka, 2002
Rilpivirine	6.1		8-fluorescein-cAMP	HEK293-OATP1B3	Weiss, 2013
Ritonavir⁴	3.6	2.5	Cholyl-glycylamido-fluorescein (CGamF)	CHO-OATP1B3	Annaert, 2010
Ritonavir⁴	4.4	4	Estradiol-17beta-glucuronide^1,2	HEK293-OATP1B3	Karlgren, 2012
Rosiglitazone	10.9		Bromsulphthalein	HEK293-OATP1B3	Bachmakov, 2008
Roxithromycin	37		Bromsulphthalein	HEK293-OATP1B3	Seithel, 2007
Sacubitril	3.81		Estradiol-17beta-glucuronide^1,2	HEK293-OATP1B3	Ayalasomayajula, 2016
Saquinavir	4.1	2.8	Cholyl-glycylamido-fluorescein (CGamF)	CHO-OATP1B3	Annaert, 2010
Saquinavir	0.47		Estradiol-17beta-glucuronide^1,2	HEK-OATP1B3	Chiou, 2014
Sildenafil	0.8		Bosentan³	CHO-OATP1B1	Treiber, 2007
Silibinin dihemisuccinate	0.4		Amanitin	MDCK II-OATP1B3	Letschert, 2006
Silibinin dihemisuccinate	1		Bromsulphthalein	MDCK II-OATP1B3	Letschert, 2006
Simeprevir⁴	0.22		CCK-8¹	HEK293-OATP1B3	Furihata, 2014
Sinensetin	21.1		8-fluorescein-cAMP	HEK293 cells	Bajraktari-Sylejmani, 2020
Sirolimus	1.3		Mycophenolic acid 7-O-glucuronide	HEK293-OATP1B3	Farasyn, 2019
Sofosbuvir	61.9		CCK-8¹	HEK293-OATP1B3	Furihata, 2014
Sulfasalazine	12	11	Estradiol-17beta-glucuronide^1,2	HEK293-OATP1B3	Karlgren, 2012
Tangeretin	5.6		8-fluorescein-cAMP	HEK293 cells	Bajraktari-Sylejmani, 2020
Telaprevir	9.69		CCK-8¹	HEK293-OATP1B3	Furihata, 2014
Telithromycin	11		Bromsulphthalein	HEK293-OATP1B3	Seithel, 2007
Tetrabromobisphenol A	12.1		Fluorescein	CHO cells	Bruyere, 2017
Tolbutamide	10		CCK-8¹	MDCKII-OATP1B3	Meyer, 2014
Trametinib	30.82		FMTX	CHO-OATP1B3	Leibovici, 1989
Troglitazone	15.7		Estradiol-17beta-glucuronide^1,2	CHO-OATP1B3	Gui, 2008
Vincristine	11	9.8	Estradiol-17beta-glucuronide^1,2	HEK293-OATP1B3	Karlgren, 2012
Zafirlukast	4.96		FMTX	CHO-OATP1B3	Leibovici, 1989

Clinical Drug-Drug Interactions

DDI	Implicated Transporter	Interacting Drug	Affected Drug	AUC	Cmax	CLR	CL/F	t1/2	Effect on PD	Reference	More Details
DDI	Implicated Transporter	Interacting Drug	Affected Drug	Clinical PK Impact(fold change)					Effect on PD	Reference	More Details
1	ABCG2/OATPs	Atazanavir / Ritonavir⁴	Rosuvastatin^1,3	3.1	7.0	ND	ND	ND	ND	Busti, 2008	DDI 1
2	OATP1B1, OATP1B3	Atazanavir/ritonavir	Glecaprevir	6.53	4.51	ND	ND	ND		Yu, 2019	DDI 2
3	OATP1B1/OATP1B3 (ABCB1/ABCG2)	Atazanavir/ritonavir	Glecaprevir	6.53	4.51	ND	ND	ND	ND	Yu, 2019	DDI 3
4	OATP1B1, OATP1B3	Atorvastatin³	Glecaprevir/pibrentasvir	8.28	22.00	ND	ND	ND		Yu, 2019	DDI 4
5	OATP1B3	Cefiderocol	Rosuvastatin^1,3	1.18	1.25	ND	NR	1.21		Katsube, 2018	DDI 5
6	OATP1B1, OATP1B3,OATP2B1	Clarithromycin⁴	Atorvastatin³	4.45	5.38	ND	ND	ND		Jacobson, 2004	DDI 6
7	OATP1B1, OATP1B3	Clarithromycin⁴	Bosentan³	3.73	3.82	ND	0.27	NR		Markert, 2014	DDI 7
8	OATP1B1, OATP1B3,OATP2B1	Clarithromycin⁴	Pravastatin^1,3	2.11	2.28	ND	ND	ND		Jacobson, 2004	DDI 8
9	OATP1B1, OATP1B3,OATP2B1	Clarithromycin⁴	Simvastatin³	9.95	7.14	ND	ND	ND		Jacobson, 2004	DDI 9
10	ABCB1/OATPs	Cyclosporine^2,4	Docetaxel³	7.3	5.7	ND	ND	ND	ND	Malingre, 2001	DDI 10
11	OATP1B1/OATP1B3 (CYP3A4)	Cyclosporine^2,4	Fluvastatin	3.55	4.1	ND	0.31	NS	ND	Park, 2001	DDI 11
12	ABCB1/ABCG2/OATP1B1/OATP1B3	Cyclosporine^2,4	Glecaprevir	5.08	4.51	ND	ND	ND	ND	Yu, 2019	DDI 12
13	ABCB1/OATPs	Cyclosporine^2,4	Paclitaxel³	8.5	2.0	ND	ND	ND	ND	Meerum, 1999	DDI 13
14	ABCG2/OATPs	Cyclosporine^2,4	Pitavastatin^1,3	4.6	6.6	ND	ND	ND	ND	Livalo Drug Label	DDI 14
15	OATP1B1, OATP1B3,OATP2B1	Cyclosporine^2,4	Pitavastatin^1,3	4.60	ND	ND	ND	ND		Gessner, 2019	DDI 15
16	ABCG2/OATPs	Cyclosporine^2,4	Rosuvastatin^1,3	5.0	10.6	ND	ND	ND	ND	Simonson, 2004	DDI 16
17	ABCG2/OATPs	Cyclosporine^2,4	Rosuvastatin^1,3	6.4	18.2	ND	ND	ND	ND	Simonson, 2004	DDI 17
18	ABCB1/ABCG2/OATP1B1/OATP1B3	Cyclosporine^2,4	Voxilaprevir	9.73	14.29	ND	ND	ND	ND	Yu, 2019	DDI 18
19	ABCG2/OATP1B1/OATP1B3	Darolutamide	Rosuvastatin^1,3	~5	~5	NS	ND	NS	ND	Zurth, 2019	DDI 19
20	ABCG2/OATP	Elvitegravir + Cobicistat	Rosuvastatin^1,3	1.38	1.89	ND	ND	ND		Custodio, 2014	DDI 20
21	ABCB1/OATPs	Erythromycin⁴	Simvastatin³	6.2	3.5	ND	ND	NS	ND	Kantola, 1998	DDI 21
22	OATP1B1/OATP1B3 (CYP3A)	Glecaprevir/pibrentasvir	Atorvastatin³	8.28	22	ND	ND	ND	ND	Yu, 2019	DDI 22
23	ABCB1/OATPs	Indinavir / Ritonavir⁴	Fexofenadine³	4.8	2.5	ND	0.2	0.7	ND	Kharasch, 2009	DDI 23
24	OATPs	Lopinavir / Ritonavir⁴	Rosuvastatin^1,3	2.1	4.7	ND	0.5	NS	yes	Kiser, 2008	DDI 24
25	OATP1B1, OATP1B3,OATP2B1	Rifamin	Pitavastatin^1,3	5.70	4.36	ND	ND	0.75		Prueksaritanont, 2014	DDI 25
26	OATP1B1, OATP1B3,OATP2B1	Rifamin	Rosuvastatin^1,3	4.37	9.93	ND	ND	0.24		Prueksaritanont, 2014	DDI 26
27	OATP1B1/OATP1B3	Rifampicin²	Glecaprevir	8.55	6.52	ND	ND	ND	ND	Yu, 2019	DDI 27
28	OATPs	Rifampicin²	Glyburide³	2.2	1.8	NS	0.5	ND	yes	Zheng, 2009	DDI 28
29	OATP1B1/OATP1B3	Rifampicin²	Voxilaprevir	7.96	8.74	ND	ND	ND	ND	Yu, 2019	DDI 29
30	ABCB1/OATPs	Ritonavir⁴	Digoxin	1.9	ND	0.6	0.6	2.6	ND	Ding, 2004	DDI 30
31	ABCB1/OATPs	Ritonavir⁴	Saquinavir	29.9	22.5	ND	ND	ND	ND	la, 2007	DDI 31
32	ABCB1/OATP1B1/OATP1B3 (CYP3A)	Simeprevir⁴	Atorvastatin³	2.12	1.7	ND	ND	ND	ND	Simeprevir NDA application	DDI 32
33	OATP1B1/OATP1B3	Simeprevir⁴	Rosuvastatin^1,3	2.81	3.17	ND	ND	ND	ND	Simeprevir NDA application	DDI 33
34	ABCG2/OATP	Tipranavir + Ritonavir	Rosuvastatin^1,3	1.37	2.23	ND	ND	ND		Pham, 2009	DDI 34
35	ABCB1/OATPs	Verapamil	Simvastatin³	4.6	2.6	ND	ND	NS	ND	Kantola, 1998	DDI 35
36	ABCG2/OATP1B1/OATP1B3	Voxilaprevir	Rosuvastatin^1,3	7.35	17.96	ND	ND	ND	ND	Yu, 2019	DDI 36

The transporters are implicated by in vitro data and/or studies in humans with genetic polymorphisms of the transporter
DDI = Drug Drug Interaction
PK = pharmacokinetic
PD = pharmacodynamic
ND = not determined
NS = not significant
N/A = information not available
Calculation of Fold Change: fold change in the presence of the interacting drug = (value with interacting drug)/(value without interacting drug)
fold change > 1: increase in pharmacokinetic value
fold change < 1: decrease in pharmacokinetic value
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022